Skip to content

We are the oldest registered charity in England/Wales as well as the oldest in Scotland who are here to support those who are affected with Alpha-1 Antitrypsin Deficiency. Not only do we support those affected, their families and friends, we also bring awareness of the condition to medical professionals and the general public. Our charity is run by non-paid volunteers who are either affected by Alpha-1 or have a family member who is. We have a real passion for the charity and for supporting people who are affected, their families and friends.

We produce booklets which people can view and download digitally and even request that a set be sent to them in the post for free (UK residents only)Click here to go to our booklet area on our main website.

While we have a website (, we created this website so that people can see news about Alpha-1 from around the world in a quick and easy way.
If you would like to ask us a question about Alpha-1, you can use the 'Contact Us' form.

Charity News

New Board members to our charity

Alpha-1 Awareness is a charity founded and run by volunteers to help bring awareness of AATD as well as give support to those

Alpha-1 Awareness donate £10,000 to the research of a cure

Alan Wooler, David Lomas & Emma Wooler   On Monday 3rd February 2020, Alan and Emma Wooler of Alpha-1 Awareness went to UCL

New promotion, New Board Member and New website!

We at Alpha-1 Awareness have some wonderful news that we would like to share with you. Internal Promotion Glyn Cockaday joined our charity

Alpha-1 in the Press

Non-profit Group grants Richland girl’s American Ninja Warrior wish

RICHLAND, WA- The Wishing Star Foundation is a non-profit based out of Spokane that grants the wishes of children ages 3-21 with terminal, life threatening

RCSI team to start trial for promising Covid-19 therapy for severe infections

Researchers in Ireland are hoping to add to the growing list of drug candidates for the treatment of patients with severe Covid-19 infection.

Double-lung transplant patient and father of three survives COVID-19

MOUNT PLEASANT (WJRT) (4/21/2020) – At 37, Paul DeWyse was diagnosed with a rare disease called alpha 1 antitrypsin deficiency. “Basically that is your

Other Alpha-1 Group’s News

AlphaNet Announces New Appointment to the Board of Directors

AlphaNet is pleased to announce the appointment of Dell Witcher to the board of directors, effective May 14, 2020. “Dell’s expertise and involvement

Research Priorities in Alpha-1 antitrypsin deficiency (AATD)

We need your help! Being led by the European Alpha-1 Research Collaboration (EARCO), a survey has been created to give us all input

CSL Behring employees ride with Alpha-1 Foundation Team for Escape to the Cape.

Two dozen CSL Behring employees are pedaling the highways and byways of Cape Cod, Massachusetts, this weekend as part of the Alpha 1




General Research

Largest Source of AATD Stem Cells Collected

Researchers from the Center for Regenerative Medicine (CReM) have assembled the largest repository of patient derived stem cells (iPSCs) from patients with alpha-1

Researchers build a better lung model

(Boston)–Using a combination of pluripotent stem cells (cells that can potentially produce any cell or tissue type) and machine learning (artificial intelligence that

Research Priorities in Alpha-1 antitrypsin deficiency (AATD)

We need your help! Being led by the European Alpha-1 Research Collaboration (EARCO), a survey has been created to give us all input

Treatment Research & Trials

First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency

Z Factor Ltd, a Cambridge-based drug development company spun out of the University of Cambridge, announced that the first human volunteer was dosed

Arrowhead Pharmaceuticals: Pushing the Boundaries of Gene Silencing

RNA interference (RNAi), sometimes called gene silencing, is an approach to therapeutics in certain diseases that are caused by the production of abnormal

Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

LEXINGTON, Mass.–(BUSINESS WIRE)–Dec. 17, 2019– Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced


Danish Medicines Council Grants Approval for CSL Behring’s Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

HATTERSHEIM AM MAIN, Germany, Jan. 24, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision,

CSL Behring lift their precautionary distribution hold on ZEMAIRA®

The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of

Diplomat signs exclusive practice-based infusion agreement with Allergy Partners

FLINT, Mich., Aug. 8, 2019 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), is pleased to announce an exclusive agreement between Diplomat and Allergy Partners, P.A., to manage in-office




Help and Advice

European Lung Foundation advise on planning a flight

ELF (European Lung Foundation) has produced a poster to help make people with lung conditions aware of the steps they should take when

Other Articles

Health Benefits of Air Pollution Reduction

Reducing air pollution improves people’s health very quickly, reports a paper from the Forum of International Respiratory Societies (FIRS). Air pollution is when

Michigan becomes first state to ban flavored e-cigarettes

Michigan becomes the first state to ban flavored e-cigarettes for minors starting today. Governor Gretchen Whitmer has been making a push to get nicotine out

First U.S. death caused by vaping confirmed in Illinois

The first reported death tied to vaping in the United States was confirmed on Friday by officials from the Illinois Department of Public Health.

© 2019 Alpha-1 Awareness